• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy and Safety of Novel Oral Anticoagulants in Patients with Cervical Artery Dissections
We report on the use, safety, and efficacy of NOACs in the treatment of CAD. Methods: We retrospectively identified patients diagnosed with CAD at a single academic center between January 2010 and August 2013. Patients were categorized by their antithrombotic treatment at hospital discharge with a NOAC (dabigatran, rivaroxaban, or apixaban), traditional anticoagulant (AC: warfarin or treatment dose low-molecular weight heparin), or antiplatelet agent (AP: aspirin, clopidogrel, or aspirin/extended-release dypyridamole). Using appropriate tests, we compared the baseline medical history, presenting clinical symptoms and initi...
Source: Cerebrovascular Diseases - November 12, 2014 Category: Neurology Source Type: research

New aspects of stroke medicine.
Abstract Systemic thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) remains the only effective and approved medical treatment of acute ischemic stroke. Several studies have demonstrated the importance of rapid recanalization. The efficacy of thrombectomy has so far not been sufficiently shown in randomized clinical trials; therefore, inclusion of suitable patients in one of the currently ongoing randomized trials is of great importance. The early treatment with magnesium after acute ischemic stroke during the pre-hospital phase did not prove to be neuroprotective. Intermittent pneumatic compr...
Source: Der Nervenarzt - June 28, 2014 Category: Neurology Authors: Diener HC, Frank B, Hajjar K, Weimar C Tags: Nervenarzt Source Type: research

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry
Discussion: Our pilot data indicate that dabigatran appears to be safe for secondary stroke prevention during the first year of implementation of this therapy. However, high cost may limit the long-term treatment of AF patients with dabigatran, leading to early discontinuation.
Source: Therapeutic Advances in Neurological Disorders - April 22, 2014 Category: Neurology Authors: Tsivgoulis, G., Krogias, C., Sands, K. A., Sharma, V. K., Katsanos, A. H., Vadikolias, K., Papageorgiou, S. G., Heliopoulos, I., Shiue, H., Mitsoglou, A., Liantinioti, C., Athanasiadis, D., Giannopoulos, S., Piperidou, C., Voumvourakis, K., Alexandrov, A. Tags: Original Research Source Type: research